The “Digital Solutions for Biomarkers Market by Content of Solution (Standalone Software Solutions
Key Inclusions
§ An overview of the currentmarket landscape of digital solutions for biomarkers, including information oncurrent status (approved, marketed, USFDA submission, research anddevelopment, proof-of-concept, and discovery), content of solution (combinationoffering of software application /gaming solution + AI support or device or personal coach, and standalonesoftware / gaming solution ), purpose of solution (diagnosis, earlyscreening, monitoring and predictive insights), type of biomarker (cognitive,idiosyncratic, molecular, neurophysiological, physiological, respiratory,vocal, and others ), target indication(s), therapeutic area(s), targetpopulation, and prescription requirement. In addition, it highlights thecompanies engaged in developing digital solutions for biomarkers, along withinformation on their year of establishment, company size, type of businessmodel used (B2B and B2C) and location of headquarters.
§ An in depth analysis of thecontemporary market trends, presented using five schematic representations,including [A] a bubble analysis comparing the leading players engaged in thedevelopment of digital solutions for biomarkers, based on various parameters (suchas product portfolio strength, type of biomarker and company size), [B] agrid representation illustrating the distribution of digital solutions forbiomarkers based on their current status, content of solution and targettherapeutic area, [C] an insightful tree map representation of digitalsolutions for biomarkers based on their therapeutic area and company size, [D]a world map representation highlighting the regional distribution of developercompanies, and [E] a comparative grid representation to highlight the currentand likely future market landscape based on status of development, type ofbiomarker and therapeutic area.
§ Elaborate profiles of prominentplayers that are either currently engaged in developing or have developeddigital solutions for biomarkers. Each company profile features a briefoverview of the company (with information on its year of establishment,number of employees, location of headquarters and key members of the executiveteam), details related to their respective product portfolios, recentdevelopments and an informed future outlook.
§ A detailed productcompetitiveness analysis of digital solutions for biomarkers taking intoconsideration several relevant parameters, such as current status, content ofsolution, purpose of solution, therapeutic area, and prescription requirement.
§ An analysis of the recent globalevents (summits / forums / conferences / annual meetings) that wereorganized for stakeholders engaged in this domain, highlighting the evolutionof discussion topics related to digital solutions for biomarkers. The chapteralso includes details on type of event, regional distribution, emergingagendas, popular organizers, and most active industry and non-industry players.
§ An elaborate analysis of theinvestments, including seed financing, venture capital financing, debtfinancing, grants / awards, made at various stages of development in companiesthat are engaged in this field, during the period 2012-2020 (till September).
§ An analysis of the partnershipsthat have been inked by stakeholders in this domain, in the period between 2014and 2020 (till September), covering marketing and distributionagreements, mergers / acquisitions, pilot programs, product / technology integrationagreements, product / technology licensing agreements, product developmentagreements, product development and commercialization agreements, productevaluation agreements, and research and development agreements.
§ An analysis of the variousdigital solutions for biomarkers focused initiatives carried out by big pharmaplayers (out of top 25 established pharmaceutical players), featuring[A] an analysis highlighting information on clinical research activity,funding, partnership activity, research publications, and participation inconferences, and [B] a spider web representation of the individualcompetitiveness of the initiatives of big pharma players based on multiplerelevant parameters.
§ An insightful discussion on how the recent COVID-19 pandemicis likely to impact the overall digital solutions for biomarkers market, alongwith information on the key initiatives undertaken by big pharma players toovercome the challenges faced due to the pandemic.
The report also features thelikely distribution of the current and forecasted opportunity across importantmarket segments, mentioned below:
§ Contentof Solution
§ Software Application+ AI Support
§ Software Application+ Device
§ Standalone SoftwareApplication
§ Other Contents ofSolutions
§ Purposeof Solution
§ Diagnosis
§ EarlyScreening
§ Monitoring
§ PredictiveInsights
§ Typeof Biomarker
§ CognitiveBiomarkers
§ IdiosyncraticBiomarkers
§ PhysiologicalBiomarkers
§ VocalBiomarkers
§ OtherBiomarkers
§ TherapeuticAreas
§ AutoimmuneDisorders
§ CardiovascularDisorders
§ InfectiousDisorders
§ MentalHealth Problems
§ NeurologicalDisorders
§ RespiratoryDisorders
§ SubstanceUse Disorders
§ Others
§ BusinessModel
§ Businessto Business (Healthcare Providers, Payers, Employers andPharmaceutical Companies)
§ Businessto Consumer (Patients and Caregivers)
§ KeyGeographical Regions
§ NorthAmerica
§ Europe
§ Asia-Pacific
§ MiddleEast and North Africa (MENA)
§ Restof the world
Thereport includes detailed transcripts of discussions held with the followingexperts:
§ Edouard Gasser(Co-Founder and Chief Executive Officer, Tilak Healthcare)
§ Michael Seggev (Chief CommercialOfficer, VocalisHealth)
To request sample pages, pleasevisit https://www.rootsanalysis.com/reports/digital-biomarkers-market/request-sample.html
Key Questions Answered
§ Who are the leading players engaged in the development of digitalsolutions for biomarkers?
§ Which are the popular therapeutic areas where digitalbiomarkers are currently relevant?
§ What kind of global level events related to digitalbiomarkers, have been organized in the recent past?
§ What is the trend of capital investments in the digitalbiomarkers market?
§ Which partnership models are most commonly adopted bystakeholders in this industry?
§ What is the tole of big pharma players engaged in thisdomain?
§ How has the COVID-19 pandemic impacted the digitalbiomarkers market?
§ What are the opportunities available for digital solutionsfor biomarkers in emerging markets?
§ How is the current and future opportunity likely to bedistributed across key market segments?
§ What are the anticipated future trends related to digitalsolutions for biomarkers market?
Youmay also be interested in the following titles:
1. AI-based DrugDiscovery Market: Focus on Deep Learning and Machine Learning, 2020-2030
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
